Our results showed that the combination of 7c and olaparib synergistically inhibited FLT3-ITD+ AML cells, revealing that an FLT3 inhibitor and a PARP inhibitor could be a promising therapeutic approach for FLT3-ITD+ AML. Here, FLT3 is linked to acute myeloid leukemia.